World's Best Scientists 2026 revealed!

D-Index & Metrics

Chemistry

D-Index
68
Citations
13706
World Ranking
6683
National Ranking
2010

Biology and Biochemistry

D-Index
70
Citations
14335
World Ranking
7156
National Ranking
3284

Joseph P. Vacca publication distribution in Chemistry in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Chemistry in 2026. The highlighted bar marks where Joseph P. Vacca sits on this spectrum.

61–80 publications: 66 scientists 81–100 publications: 302 scientists 101–120 publications: 623 scientists 121–140 publications: 918 scientists 141–160 publications: 1,218 scientists 161–180 publications: 1,350 scientists 181–200 publications: 1,344 scientists 201–220 publications: 1,281 scientists 221–240 publications: 1,216 scientists 241–260 publications: 1,100 scientists 261–280 publications: 979 scientists 281–300 publications: 939 scientists 301–320 publications: 764 scientists 321–340 publications: 643 scientists 341–360 publications: 628 scientists 361–380 publications: 522 scientists 381–400 publications: 459 scientists 401–420 publications: 397 scientists 421–440 publications: 327 scientists 441–460 publications: 270 scientists 461–480 publications: 265 scientists 481–500 publications: 252 scientists 501–520 publications: 201 scientists 521–540 publications: 185 scientists 541–560 publications: 148 scientists 561–580 publications: 148 scientists 581–600 publications: 132 scientists 601–620 publications: 114 scientists 621–640 publications: 104 scientists 641–660 publications: 91 scientists 661–680 publications: 92 scientists 681–700 publications: 73 scientists 701–720 publications: 57 scientists 721–740 publications: 54 scientists 741–760 publications: 67 scientists 761–780 publications: 45 scientists 781–800 publications: 46 scientists 801–820 publications: 39 scientists 821–840 publications: 32 scientists 841–860 publications: 36 scientists 861–880 publications: 29 scientists 881–900 publications: 26 scientists 901–920 publications: 24 scientists 921–940 publications: 14 scientists 941–960 publications: 23 scientists 961–980 publications: 28 scientists 981–1,000 publications: 15 scientists 1,001–1,020 publications: 29 scientists 1,021–1,040 publications: 12 scientists 1,041–1,060 publications: 19 scientists 1,061–1,080 publications: 12 scientists 1,081–1,100 publications: 6 scientists 1,101–1,120 publications: 8 scientists 1,121–1,140 publications: 12 scientists 1,141–1,160 publications: 5 scientists 1,161–1,180 publications: 6 scientists 1,181–1,200 publications: 14 scientists 1,201–1,220 publications: 7 scientists 1,221–1,240 publications: 2 scientists 1,241–1,260 publications: 6 scientists 1,261–1,280 publications: 4 scientists 1,281–1,294 publications: 6 scientists 1,295+ publications: 100 scientists
61 publications 1,295+

This scientist: 241 publications — 47th percentile

47% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,295 publications or more.

Joseph P. Vacca D-index placement in Chemistry in 2026

The chart shows the D-index (discipline H-index) distribution of Chemistry scientists ranked by Research.com in 2026. The highlighted bar marks where Joseph P. Vacca sits on this spectrum.

40–41 D-Index: 289 scientists 42–43 D-Index: 612 scientists 44–45 D-Index: 808 scientists 46–47 D-Index: 776 scientists 48–49 D-Index: 835 scientists 50–51 D-Index: 861 scientists 52–53 D-Index: 872 scientists 54–55 D-Index: 933 scientists 56–57 D-Index: 1,051 scientists 58–59 D-Index: 930 scientists 60–61 D-Index: 882 scientists 62–63 D-Index: 834 scientists 64–65 D-Index: 731 scientists 66–67 D-Index: 775 scientists 68–69 D-Index: 683 scientists 70–71 D-Index: 646 scientists 72–73 D-Index: 561 scientists 74–75 D-Index: 501 scientists 76–77 D-Index: 437 scientists 78–79 D-Index: 388 scientists 80–81 D-Index: 354 scientists 82–83 D-Index: 292 scientists 84–85 D-Index: 275 scientists 86–87 D-Index: 254 scientists 88–89 D-Index: 235 scientists 90–91 D-Index: 185 scientists 92–93 D-Index: 192 scientists 94–95 D-Index: 155 scientists 96–97 D-Index: 163 scientists 98–99 D-Index: 125 scientists 100–101 D-Index: 105 scientists 102–103 D-Index: 105 scientists 104–105 D-Index: 112 scientists 106–107 D-Index: 88 scientists 108–109 D-Index: 68 scientists 110–111 D-Index: 69 scientists 112–113 D-Index: 65 scientists 114–115 D-Index: 79 scientists 116–117 D-Index: 61 scientists 118–119 D-Index: 44 scientists 120–121 D-Index: 37 scientists 122–123 D-Index: 40 scientists 124–125 D-Index: 33 scientists 126–127 D-Index: 26 scientists 128–129 D-Index: 34 scientists 130–131 D-Index: 35 scientists 132–133 D-Index: 25 scientists 134–135 D-Index: 27 scientists 136–137 D-Index: 17 scientists 138–139 D-Index: 16 scientists 140–141 D-Index: 20 scientists 142–143 D-Index: 20 scientists 144–145 D-Index: 15 scientists 146–147 D-Index: 9 scientists 148–149 D-Index: 9 scientists 150–151 D-Index: 16 scientists 152–153 D-Index: 11 scientists 154–155 D-Index: 9 scientists 156–157 D-Index: 3 scientists 158 D-Index: 3 scientists 159+ D-Index: 98 scientists
40 D-Index 159+

This scientist: 68 D-Index — 64th percentile

64% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 159 D-Index or more.

Overview

Joseph P. Vacca is affiliated with MSD in the United States and has an extensive background in research within biochemistry, genetics, and molecular biology, with a focus also on medicine. Their work spans molecular biology, pulmonary and respiratory medicine, oncology, cancer research, and immunology.

Their research frequently addresses topics such as prostate cancer treatment and research, cancer-related molecular pathways, advanced breast cancer therapies, cancer genomics and diagnostics, CRISPR and genetic engineering, immune cell function and interaction, and protein degradation and inhibitors.

Among their recent publications are:

  • "Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors," 2020, published in Cell chemical biology
  • "Discovery of KB-0742, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of CDK9 for MYC-Dependent Cancers," 2023, published in Journal of Medicinal Chemistry
  • "Abstract P228: Preclinical pharmacokinetics and pharmacodynamics of KB-0742, a selective, oral CDK9 inhibitor," 2021, published in Molecular Cancer Therapeutics
  • "Abstract 7121: The novel WEE1i, APR-1051, is a potentially well tolerated and effective treatment for cyclin E-overexpressing cancers," 2024, published in Cancer Research
  • "Abstract 6177: ATRN-119 and ATRN-W1051: Novel and potentially well tolerated ATR and WEE1 inhibitors for targeted cancer treatment," 2023, published in Cancer Research

Joseph P. Vacca has frequently published in venues including:

  • Cancer Research
  • Molecular Cancer Therapeutics
  • Regular and Young Investigator Award Abstracts
  • Cell chemical biology
  • Journal of Medicinal Chemistry

Frequent co-authors in their research include Eric J. Brown, Oren Gilad, David B. Freeman, Molly M. Hansbarger, and Peter Mikochik.

Best Publications

  • L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor

    J P Vacca;B D Dorsey;W A Schleif;R B Levin

  • Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes.

    Jay A. Grobler;Kara Stillmock;Binghua Hu;Marc Witmer

  • L-735,524 : the design of a potent and orally bioavailable HIV protease inhibitor

    B D Dorsey;R B Levin;S L McDaniel;J P Vacca

  • A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase.

    Daria J. Hazuda;Neville J. Anthony;Robert P. Gomez;Samson M. Jolly

  • Structure-Based Design of Potent and Selective Cell-Permeable Inhibitors of Human β-Secretase (BACE-1)

    Shawn J. Stachel;Craig A. Coburn;Thomas G. Steele;Kristen G. Jones

  • Integrase Inhibitors and Cellular Immunity Suppress Retroviral Replication in Rhesus Macaques

    Daria J. Hazuda;Steven D. Young;James P. Guare;Neville J. Anthony

  • Design and Synthesis of 8-Hydroxy-[1,6]Naphthyridines as Novel Inhibitors of HIV-1 Integrase in Vitro and in Infected Cells

    Linghang Zhuang;John S. Wai;Mark W. Embrey;Thorsten E. Fisher

  • 4-Aryl-2,4-dioxobutanoic acid inhibitors of HIV-1 integrase and viral replication in cells.

    John S. Wai;Melissa S. Egbertson;Linda S. Payne;Thorsten E. Fisher

  • A priori prediction of activity for HIV-1 protease inhibitors employing energy minimization in the active site.

    M. Katharine Holloway;Jenny M. Wai;Thomas A. Halgren;Paula M. D. Fitzgerald

  • MK-5172, a Selective Inhibitor of Hepatitis C Virus NS3/4a Protease with Broad Activity across Genotypes and Resistant Variants

    Vincenzo Summa;Steven W. Ludmerer;John A. McCauley;Christine Fandozzi

  • Highly diastereoselective alkylations of chiral amide enolates: new routes to hydroxyethylene dipeptide isostere inhibitors of HIV-1 protease

    D. Askin;M. A. Wallace;J. P. Vacca;R. A. Reamer

  • Hiv protease inhibitors useful for the treatment of aids

    Joseph P. Vacca;Bruce D. Dorsey;James P. Guare;M. Katharine Holloway

  • Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity.

    Craig A. Coburn;Peter T. Meinke;Wei Chang;Christine M. Fandozzi

  • Hcv ns3 protease inhibitors

    M. Katharine Holloway;Nigel J. Liverton;Steven W. Ludmerer;John A. Mccauley

  • Pharmacological characterization of MK-0974 [N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine.

    Christopher A. Salvatore;James C. Hershey;Halea A. Corcoran;John F. Fay

  • Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1- (2,2,2-trifluoroethyl)azepan-3-yl]-4- (2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin- 1-yl)piperidine-1-carboxamide (MK-0974)

    Daniel V Paone;Anthony W Shaw;Diem N Nguyen;Christopher S Burgey

  • Discovery of Vaniprevir (MK-7009), a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor

    John A. McCauley;Charles J. McIntyre;Michael T. Rudd;Kevin T. Nguyen

  • Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor.

    Steven Harper;John A McCauley;Michael T Rudd;Marco Ferrara

  • X-Ray Crystal Structure of the HIV Protease Complex with L-700,417, an Inhibitor with Pseudo C2 Symmetry

    Roger Bone;Joseph P. Vacca;Paul S. Anderson;M. Katharine Holloway

  • Discovery of 3-{5-[(6-amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile (MK-4965): a potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses.

    Thomas J Tucker;John T Sisko;Robert M Tynebor;Theresa M Williams

  • L-687,908, a potent hydroxyethylene-containing HIV protease inhibitor.

    J P Vacca;J P Guare;S J deSolms;W M Sanders

Frequent Co-Authors

David B. Olsen
David B. Olsen MSD (United States)
Daria J. Hazuda
Daria J. Hazuda MSD (United States)
Harold G. Selnick
Harold G. Selnick MSD (United States)
Arun K. Ghosh
Arun K. Ghosh Purdue University West Lafayette
Shaun R. Stauffer
Shaun R. Stauffer Cleveland Clinic
Michael D. Miller
Michael D. Miller United States Military Academy
Jules A. Shafer
Jules A. Shafer MSD (United States)
Samuel Graham
Samuel Graham Georgia Institute of Technology
Ian W. Davies
Ian W. Davies Princeton University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring Chemistry in the USA opens doors to a variety of related career paths and educational opportunities. For those interested in complementing their Chemistry background with legal expertise, criminal justice associate programs online offer foundational knowledge that can lead to careers in regulatory affairs or forensic science.

If you’re drawn to the legal field itself, degrees for paralegals provide a practical route to engage with legal processes, which can be instrumental when working with patent law or chemical regulations. Learning about these degrees can inform your decision if you want to blend science with legal skills.

Chemistry graduates often pursue careers in the pharmaceutical industry. Understanding the role of a pharmaceutical sales representative, including typical drug rep salary and job outlook, can guide those interested in bridging science and business.

For those aiming for a more specialized healthcare career, becoming a pharmacist requires specific training and qualifications. Reviewing the pharmacist education requirements is key to understanding the time and commitment needed for this respected profession.

Best Scientists Citing Joseph P. Vacca

Trending Scientists

Recently Published Articles